è±åœã®COVID-19å
¥é¢æ£è
ã«ãããHIVéœæ§äŸãšéHIVéœæ§äŸã®æ¯èŒïŒæµ·å€ããŒã¿ïŒ
28æ¥ç®ãŸã§ã®çŽ¯ç©æ»äº¡çã¯HIVéœæ§è 26.7%ãéHIVéœæ§è 32.1%ã§éãã¯ãªãã£ããã®ã®ã60æ³æªæºã®æ£è ã§ã¯HIVéœæ§è ã§æ»äº¡çãææã«é«ããªããŸããã21.3% vs. 9.6%; P<0.001ïŒlog-rank testïŒãã幎霢ã§èª¿æŽåŸã®æ»äº¡ãªã¹ã¯ã¯HIVéœæ§è ã§é«ãïŒèª¿æŽåŸHR 1.47; 95% CI 1.01-2.14; P=0.05ïŒãä»ã®å åã§èª¿æŽåŸïŒèª¿æŽåŸHR 1.69; 95% CI 1.15-2.48; P=0.008ïŒã60æ³æªæºã®æ£è ã«éå®ãã解æïŒèª¿æŽåŸHR 2.87; 95% CI 1.70-4.84; P<0.001ïŒã§ã¯ææã«é«ããªããŸããã
28æ¥ç®ãŸã§ã®çŽ¯ç©æ»äº¡çã¯HIVéœæ§è 26.7%ãéHIVéœæ§è 32.1%ã§éãã¯ãªãã£ããã®ã®ã60æ³æªæºã®æ£è ã§ã¯HIVéœæ§è ã§æ»äº¡çãææã«é«ããªããŸããã21.3% vs. 9.6%; P<0.001ïŒlog-rank testïŒãã幎霢ã§èª¿æŽåŸã®æ»äº¡ãªã¹ã¯ã¯HIVéœæ§è ã§é«ãïŒèª¿æŽåŸHR 1.47; 95% CI 1.01-2.14; P=0.05ïŒãä»ã®å åã§èª¿æŽåŸïŒèª¿æŽåŸHR 1.69; 95% CI 1.15-2.48; P=0.008ïŒã60æ³æªæºã®æ£è ã«éå®ãã解æïŒèª¿æŽåŸHR 2.87; 95% CI 1.70-4.84; P<0.001ïŒã§ã¯ææã«é«ããªããŸããã